Invisible Work of Rare Pharmacy Delivers Highly Visible Patient Outcomes

Today's guest post comes from Jay Weaver, VP, Payer Solutions at PANTHERx^® Rare.

Jay describes the clinical and operational work that often happens behind the scenes at a Rare Pharmacy. He explains how these capabilities—including greater personalization, real-world evidence, and specialized clinical expertise—can support therapeutic success and help payers assess the value of Rare Pharmacy .

To learn more about the PANTHERx approach to Rare Pharmacy, download their guide, Five Criteria for Payers to Evaluate a Rare-focused Specialty Pharmacy.

Read on for Jay's insights.

Invisible Work of Rare Pharmacy Delivers Highly Visible Patient Outcomes
By Jay Weaver, VP, Payer Solutions, PANTHERx Rare

Rare disease therapies are among the most clinically complex and expensive treatments in healthcare. The difficult and often hidden clinical and operational work performed by a Rare Pharmacy is what helps patients and prescribers realize the full value of these therapies, including saving, improving, and extending lives. Yet much of that value remains invisible when viewed through a traditional specialty pharmacy (SP) lens.

For example, rare therapies don’t fit neatly into the evaluation and management frameworks that PBMs developed over time. Utilization management, evidence review, and cost containment strategies were built for chronic conditions, often with multiple approved therapies and large patient populations, to enable predictable forecasting. These same strategies do not always translate to rare and ultra-rare conditions.

Reshaping the value conversation

Just as the science to treat rare diseases evolves, so must our understanding of the economics. Here are three considerations for payers, PBMs, and employer groups as they assess the value of Rare Pharmacy:

1. High personalization can uncover hidden value.
Patient education, counseling, and support continue long after the package lands on the patient’s doorstep, often at a level of intensity and duration not required in traditional SPs. Rare Pharmacy delivers an ongoing clinical relationship that involves repeated patient touchpoints, coordination with prescribers, treatment education, adherence support, benefits navigation, monitoring, and interventions when challenges arise. Much of this work occurs behind the scenes, but it is often the difference between a therapy that is prescribed and a therapy that succeeds.

2. Rare treatments are expensive, more so if they don’t work.
A single approved rare therapy can consume an entire benefit-year budget or exceed a self-funded employer's stop-loss threshold (eg, individual injectable drug claims already reaching seven figures). In this environment, therapeutic benefit matters. Rare Pharmacy helps maximize the likelihood of success through specialized clinical support, proactive interventions, and ongoing patient engagement.

3. Hyper-personalized treatment can reduce downstream costs.
Payers appropriately focus on matching treatments to the patients most likely to benefit,

but that approach often overlooks a broader reality: medical utilization, disability, caregiver burden, and lost productivity frequently account for more of the total disease cost than the drug itself. And because many rare diseases carry outsized clinical consequences for missed or delayed doses, identifying the right patient—and keeping them on therapy—matters more than in other therapeutic categories.

Patients who remain adherent to life-changing therapies are more likely to avoid complications, preserve function, reduce unnecessary healthcare utilization, and realize the outcomes that justified treatment in the first place.

Five ways Rare Pharmacy bridges payer gaps

A Rare Pharmacy like PANTHERx Rare—built specifically around rare patients rather than general specialty drug management—can address these considerations in ways most payers cannot replicate internally, through:

1. Disease-specific clinical expertise
Clinical teams dedicated to rare conditions and treatments develop a deep understanding of disease progression and caregiver burden, enabling earlier interventions that help prevent discontinuation and avoidable complications.

2. Real-world evidence generation
Longitudinal patient registries and outcomes tracking supplement clinical trial data, giving payers evidence of total cost-of-care offsets—not just acquisition cost—to justify continued coverage decisions.

3. Patient identification and care coordination
A rare-focused pharmacy helps confirm appropriate therapy candidates and coordinate directly with the case managers whom payers have assigned to high-cost claimants, reducing inappropriate use and supporting confident dispensing decisions.

4. High-touch adherence and clinical management
Tailored programs that track adherence and outcomes help demonstrate that high cost can generate high value, while close prescriber relationships ensure swift coordination when treatment concerns arise.

5. Specialized accreditation, operations, and quality oversight
Exclusive and limited distribution capabilities, cold chain logistics, and risk evaluation and mitigation strategy program management reduce dispensing risk, while dual accreditation (eg, URAC and ACHC) and third-party quality reviews give payers confidence in the appropriateness of treatment and a reliable signal for network inclusion decisions.

Value of Rare Pharmacy extends before dispensing and after delivery
Since many rare therapies are high cost, it is in all stakeholders’ interest to ensure that a therapy is dispensed to the appropriate patients who are then counseled, closely monitored, and supported collaboratively to increase therapeutic success.

In theory, it sounds straightforward, but in practice, Rare Pharmacy is hard.

Many rare journeys involve cold chain and other precision logistics, intricate titration schedules, safety monitoring, regular laboratory assessments, and frequent patient, prescriber, and insurer touchpoints. That complexity requires more clinical interventions, coordination, expertise, and patient engagement than traditional SP models. But the reward for that additional effort is substantial: improved adherence, stronger persistence, better patient experiences, and more successful therapeutic outcomes.

My hope is that this post sparks a new conversation about how rare patients and therapies require a pharmacy model as unique as they are.

Download a new resource from PANTHERx to learn more about how payers can better evaluate a Rare Pharmacy: Five Criteria for Payers to Evaluate a Rare-focused Specialty Pharmacy.

---

Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish a guest post on Drug Channels, please contact Marie Caldwell (mcaldwell@hmpglobal.com).